While many think of the progression of Alzheimer’s mostly as a cognitive process, the mind and body are inherently linked. A new three-year project at Michigan Technological University, funded by the National Institutes of Health, explores that link.
A West Virginia University graduate student is studying how certain cells affect the development of this part of the brain, and therefore, how they could affect how quickly and accurately the brain processes sounds.
Analysis of data captured during a long-term study of aging adults shows that those who report being very sleepy during the day were nearly three times more likely than those who didn’t to have brain deposits of beta amyloid, a protein that’s a hallmark for Alzheimer’s disease, years later.
Scientists seek to better understand protein folding to cure misfolding diseases, but this incredibly complex process requires sophisticated algorithms to identify the folding mechanisms. Computational biophysicists have proposed a new way to identify the most crucial factors for protein folding. They demonstrated the short simulation time of their approach on a small but intriguing protein, “GB1 beta-hairpin,” in The Journal of Chemical Physics.
Aliviado—which means “relief” in Portuguese—aims to provide relief to people living with dementia and their caregivers through helping home health and hospice agencies provide high-quality, compassionate care.
Tiny protein structures called amyloids are key to understanding certain devastating age-related diseases. Aggregates, or sticky clumped-up amyloids, form plaques in the brain, and are the main culprits in the progression of Alzheimer’s and Huntington’s diseases.Amyloids are so tiny that they can’t be visualized using conventional microscopic techniques.
Researchers at the University of Florida have discovered that a modified version of an important immune cell protein could be used to treat Alzheimer’s disease. The study, which will be published August 29 in the Journal of Experimental Medicine, reveals that soluble versions of a protein called TLR5 can reduce the buildup of amyloid plaques in the brains of Alzheimer’s disease model mice and prevent the toxic peptide that forms these plaques from killing neurons.
Using technology similar to what is found in many eye doctors’ offices, researchers at Washington University School of Medicine in St. Louis have detected evidence suggesting Alzheimer’s in older patients who had no symptoms of the disease.
Dthera™ Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.
A new study, authored by Anthony Bardo and Scott Lynch, examines "cognitive life expectancy." What exactly does that term mean? Bardo, an assistant professor of sociology at the University of Kentucky, describes "cognitive life expectancy" as how long older adults live with good versus declining brain health.
Tulane University research could shed light on the molecular details of Alzheimer’s and Parkinson’s.
A University of Adelaide-led team of scientists has suggested a potential link between iron in our cells and the rare gene mutations that cause Alzheimer’s disease, which could provide new avenues for future research.
Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing the broad patterns of genetic contributions to traits and diseases.
Johns Hopkins Medicine researchers say a study designed to see if reducing the amount of anesthesia reduces the risk of postoperative delirium in older patients surprisingly found that lighter sedation failed to do so in severely ill people undergoing hip fracture repair.
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, today announced the launch of Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, including the Institute for Applied Cancer Science (IACS) and the Neurodegeneration Consortium (NDC).
Reduced levels of a chaperone protein might have implications for the development of Parkinson’s disease and Lewy body dementia, according to new research from UAB. Chaperone protein 14-3-3 could lead to misfolding and spread of alpha-synuclein.
• Older adults who initiate dialysis for kidney failure face a higher likelihood of being diagnosed with dementia and Alzheimer’s disease. • Certain risk factors were linked this higher risk. • Older hemodialysis patients with a diagnosis of dementia or Alzheimer’s disease had a high risk of early death.
Older kidney disease patients who are sick enough to require the blood-filtering treatment known as dialysis are at high risk of dementia, including Alzheimer’s disease, according to a study led by scientists at Johns Hopkins Bloomberg School of Public Health.
A clinical trial being conducted at Georgetown explores if nicotine can slow or stop memory loss in people experiencing mild memory problems, or mild cognitive impairment (MCI).
There is new hope for the treatment of Alzheimer’s and other neurological diseases following a ground-breaking discovery made by an Australian-Chinese research collaboration.
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery & Development—has announced three new scholars in collaboration with its partners Foundation Fighting Blindness (FFB) and Alzheimer’s Drug Discovery Foundation (ADDF). Harrington Discovery Institute collaborates with FFB on the Gund-Harrington Award to accelerate therapies for retinal degenerative diseases and ADDF to advance the development of drugs to prevent and treat Alzheimer’s disease.
"In humans, being able to tweak levels of TTR degradation could act as a means of stopping TTR toxicity."
The process, discovered in the axons of neurons, is implicated in Alzheimer’s, amyotrophic lateral sclerosis, traumatic brain injury and other diseases or injuries to the nervous system.
Johns Hopkins Medicine scientists say they have found new evidence in lab-grown mouse brain cells, called astrocytes, that one root of Alzheimer’s disease may be a simple imbalance in acid-alkaline—or pH—chemistry inside endosomes, the nutrient and chemical cargo shuttles in cells.
More than 90 percent of people caring for a family member with dementia experience poor sleep, according to new research by the University at Buffalo School of Nursing.
Rutgers researchers will benefit from a $250,000 grant from the Gillson Longenbaugh Foundation to help expand the team’s work on neural stem cell interactions and developing antibody therapeutics for cancer treatment.
Glaucoma Research Foundation, a national non-profit organization dedicated to finding a cure for glaucoma, today announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also be applicable to other neurodegenerative diseases, including Alzheimer's disease.
Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc. (hereinafter “Janssen”) to develop and commercialize an AMYLOID β 42/40 RATIO assay.
A small population of brain cells called "mossy cells" deep in a memory-making region of the brain controls the production of new neurons and may have a role in common brain disorders, according to a study from scientists at the University of North Carolina School of Medicine.
People who feel faint, dizzy or lightheaded when standing up may be experiencing a sudden drop in blood pressure called orthostatic hypotension. Now a new study says middle-aged people who experience such a drop may have a greater risk of developing dementia or stroke decades later. The study is published in the July 25, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Preliminary results of the SPRINT MIND trial found that lowering one’s systolic blood pressure to 120 mm Hg reduces the risk of mild cognitive impairment and dementia.
The results of the first ever clinical trial of focused ultrasound to open the blood-brain barrier (BBB) in patients with Alzheimer’s disease were published today in Nature Communications and also presented at the Alzheimer’s Association International Conference (AAIC) in Chicago, Illinois. The pilot trial demonstrated the feasibility and preliminary safety of focally, reversibly and repetitively opening the BBB.
In a study published online July 25 in the journal Nature, University of California San Diego School of Medicine researchers identified a signaling pathway that activates the NLRP3 inflammasome implicated in several severe chronic inflammatory disorders.
Reduced levels of plasmalogens are associated with an increased risk of Alzheimer’s Disease, according to new research presented this week at AAIC 2018.
The National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site will begin making large-scale DNA sequence data available to investigators accelerate research.
Aberrant clearance activity of microglia in particular brain regions leads to changes associated with neurodegenerative diseases
A woman’s history of pregnancy may affect her risk of Alzheimer’s disease decades later, according to a study published in the July 18, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Roy Ervin Twyman, MD, PhD, an academic neurologist with nearly 20 years’ experience in neuroscience pharmaceutical drug development, will join the NeuroVision Imaging Inc. Board of Directors on July 20.
Recent articles in the journal Molecular & Cellular Proteomics investigate metabolic quirks of cancer cells, other roles for the enzyme that generates amyloid beta, and the action mechanism of a bacterial toxin.
Philanthropist Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder have announced a new initiative, Diagnostics Accelerator, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias.
A Johns Hopkins Medicine analysis of information gathered for an ongoing and federally sponsored study of aging and disability adds to evidence that a substantial majority of older adults with probable dementia in the United States have never been professionally diagnosed or are unaware they have been.
Most people who are familiar with the term associate it with stroke (i.e., brain damage caused by disrupted blood flow to the brain). But aphasia, an impairment of language, is not always caused by stroke.
Supplementing a single protein found in the spinal cord could help prevent symptoms of Lou Gehrig’s disease, according to a new study out of Case Western Reserve University School of Medicine. Researchers found high levels of the protein—called mitofusion 2 or Mfn2—prevented nerve degeneration, muscle atrophy, and paralysis in a mouse model of the disease. Since Mfn2 is often depleted during Lou Gehrig’s, the new study suggests supplementing it could be a novel therapeutic approach for the disease.
Alzheimer’s disease is a progressive, neurodegenerative condition that often begins with mild cognitive impairment (MCI), making early and repeated assessments of cognitive change crucial to diagnosis and treatment. In a paper in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, researchers led by scientists at the University of California San Diego School of Medicine found that repeated testing of middle-age men produced a “practice effect” which obscured true cognitive decline and delayed detection of MCI.
Older people who have higher blood pressure may have more signs of brain disease, specifically brain lesions, according to a study published in the July 11, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers also found a link between higher blood pressure and more markers of Alzheimer’s disease, tangles in the brain.
Scientists have discovered a “Big Bang” of Alzheimer’s disease – the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
New research from South Australian scientists has shown that vitamin D (also commonly known as the sunshine vitamin) is unlikely to protect individuals from multiple sclerosis, Parkinson’s disease, Alzheimer’s disease or other brain-related disorders.
Nearly all major neurodegenerative diseases are defined by the presence of one of four proteins that have gone rogue. As such, investigational drugs aimed at preventing or slowing the disease often hone in on just one of these proteins. However, targeting multiple proteins at once may be the real key, according to a recent Penn Medicine study.
A first-of-its-kind study has found that “skinny fat” – the combination of low muscle mass and strength in the context of high fat mass – may be an important predictor of cognitive performance in older adults. Results show that sarcopenic obesity or “skinny fat” was associated with the lowest performance on global cognition.
A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer’s disease pathology and protect memory, according to neurological researchers at Rush University Medical Center, who published the results of their study today in the July issue of The Journal of Neuroscience.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right